Braveheart Bio
Filed with the SEC on · accession 0001628280-26-071586
BRVE filed a 8-K (current report) with the SEC on Nov 6, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The stock moved +6.8% by the first close after the filing.
Braveheart Bio announced 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, presented with Hengrui Pharma at the American Heart Association Scientific Sessions 2026.
Close before
$17.41
Nov 5, 2026
First close after
+6.80%
$18.60
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for BRVE, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for BRVE?
Click hereBRVE filed a 8-K (SEC filing). Braveheart Bio announced 52-week open-label extension data from a Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, presented with Hengrui Pharma at the American Heart Association Scientific Sessions 2026.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
BRVE closed at $17.41 before the filing and $18.60 on Nov 6, 2026 (+6.80%).
Get alerts when BRVE files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days